Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter plotting dialysis strategy to compete with Fresenius/NMC combination.

This article was originally published in The Gray Sheet

Executive Summary

BAXTER PURSUING ALTERNATIVES TO NMC ACQUISITION after withdrawing its $3.8 bil. bid for National Medical Care in a Feb. 22 letter to W.R. Grace Chairman, President and CEO Albert Costello. Baxter says it is now considering alternatives for its dialysis business to compete with what likely will be a combined Fresenius/NMC dialysis services and supplies operation.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel